Faculty

James L. LaBelle, MD PhD

  • Professor of Pediatrics
    Committee on Cancer Biology
  • Clinical Interests: Adolescent and Young Adult Cancer Care, Childhood Leukemia, Leukemia, Lymphoma, Pediatric CAR TCell Therapy, Pediatric Oncology, Pediatric Stem Cell Transplant, Stem cell transplantation
  • Research and Scholarly Interests: bcl-2 Genes, Graft Versus Host Disease, Immunomodulatory Therapies, Regulatory T Cells
  • Websites: LaBelle Lab, Research Network Profile
  • Contact: jlabelle1@uchicago.edu
  • Graduate Program: Cancer Biology

The major goal of the laboratory is to dissect and pharmacologically target intracellular proteins to induce cancer cell death and manipulate the immune response. We are currently applying new research tools and prototype therapeutics that we, and others, have developed to target the BCL-2 family of proteins and other cell signaling proteins in immune cells.



A large part of our lab focuses on using portions of the actual proteins, or peptides, as drugs and biological tools to uncover specific molecular pathways in diseased and normal cells. Peptide-based therapeutics have enormous potential for immune modulation and direct cancer treatment but have traditionally lacked efficient stabilization and delivery within patients, and thereby, have had limited clinical applications. To are working to overcome these barriers within the lab and through collaboration with nanotechnologists and chemical engineers.



Overall, we are committed to translation of our findings to pediatric and adult patients with cancer and immune system disease. While performing research at the University of Chicago, we are in close proximity to scientists, clinicians, and patients and are deeply committed to working collaboratively with these groups to make significant inroads in treating those suffering from refractory disease.

Dana-Farber Cancer Institute/BCH
Boston, MA
Postdoctoral fellowship, Walensky Lab - Cancer Chemical Biology
2012

Dana-Farber Cancer Institute/BCH
Boston, MA
Clinical Fellow - Pediatric Hematology/Oncology
2009

Boston Children's Hospital (BCH)
Boston, MA
Intern/Resident - Pediatrics
2006

Medical College of Wisconsin
Milwaukee, WI
MD/PhD - Medicine/Immunology
2003

Lawrence University
Appleton, WI
BA - Biology
1994

MCL1 inhibition exerts potent antileukemic activity by restoring apoptosis in T-lineage acute lymphoblastic leukemia.
MCL1 inhibition exerts potent antileukemic activity by restoring apoptosis in T-lineage acute lymphoblastic leukemia. Blood Neoplasia. 2026 Nov; 3(4):100302.
PMID: 42893188

Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy.
Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy. Cancer Immunol Res. 2026 Aug 04; 14(8):1292-1306.
PMID: 42112708

Therapeutic targeting of BCL-2 during CART cell production augments potency through non-apoptotic adaptive changes.
Therapeutic targeting of BCL-2 during CART cell production augments potency through non-apoptotic adaptive changes. Signal Transduct Target Ther. 2026 Apr 27; 11(1).
PMID: 42036409

Gene Therapy for Sickle Cell Disease: Practice Recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy.
Gene Therapy for Sickle Cell Disease: Practice Recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy. Transplant Cell Ther. 2026 Jul; 32(7):778-791.
PMID: 41905703

G-CSF for Mobilizing CD34+ Cells in Individuals With SCD: A Word of Caution.
G-CSF for Mobilizing CD34+ Cells in Individuals With SCD: A Word of Caution. Am J Hematol. 2026 Jun; 101(6):1178-1181.
PMID: 41705621

Hospital-mandated restrictions during the COVID-19 pandemic alter hospital-acquired viral respiratory infections during hematopoietic stem cell transplantation: a single center pediatric experience.
Hospital-mandated restrictions during the COVID-19 pandemic alter hospital-acquired viral respiratory infections during hematopoietic stem cell transplantation: a single center pediatric experience. Antimicrob Steward Healthc Epidemiol. 2025; 5(1):e327.
PMID: 41446423

Tumor nutrient stress gives rise to a drug tolerant cell state in pancreatic cancer.
Tumor nutrient stress gives rise to a drug tolerant cell state in pancreatic cancer. bioRxiv. 2025 Sep 08.
PMID: 40964288

Normalization of Cerebral Hemodynamics After Gene Therapy in Adults With Sickle Cell Disease.
Normalization of Cerebral Hemodynamics After Gene Therapy in Adults With Sickle Cell Disease. Am J Hematol. 2025 Oct; 100(10):1882-1885.
PMID: 40576267

Low-Strength Type I Interferon Signaling Promotes CAR T-Cell Treatment Efficacy.
Low-Strength Type I Interferon Signaling Promotes CAR T-Cell Treatment Efficacy. bioRxiv. 2025 May 20.
PMID: 40463198

Venetoclax Induces BCL-2-Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti-PD-1 Checkpoint Blockade.
Venetoclax Induces BCL-2-Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti-PD-1 Checkpoint Blockade. Cancer Immunol Res. 2024 08 01; 12(8):1074-1089.
PMID: 38810242

View All Publications

Hyundai Hope on Wheels Scholar Award
2018

Hoogland Lymphoma Pilot Project Award
2016

AbbVie-UChicago Collaboration in Oncology Award
2016

Comer Children's Hospital Development Board Award
2015

United-4a Cure Research Award
2014

Hyundai Hope on Wheels Scholar Award
2014

James B. Nachman Fellow
2013

Cancer Research Foundation Young Investigator's Award
2012

AACR-Aflac Scholar-in-Training Award
2011

Leukemia and Lymphoma Society Special Fellow Award
2010

Lauri Strauss Leukemia Foundation Research Award
2007

Senior Resident Teaching Award
2006

Proctor and Gamble Teaching and Tomorrow Award
2004

First Place, Research Trainee Award
2001

Botanical Society of America Merit Award
1994

Phi Sigma Award in Biology
1994

Engstrom Scholars Award
1992